Halozyme Therapeutics (HALO) News Today $61.19 +1.16 (+1.93%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$60.80 -0.39 (-0.64%) As of 08:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period ArrowMark Colorado Holdings LLC Sells 500,144 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)ArrowMark Colorado Holdings LLC trimmed its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 24.9% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 1,510,511 shares of the biopharmaceutical company's stock after selling 50May 5 at 6:47 AM | marketbeat.comCaisse DE Depot ET Placement DU Quebec Purchases 263,570 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Caisse DE Depot ET Placement DU Quebec lifted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 280.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 357,579 shares of the biopharmaMay 5 at 5:28 AM | marketbeat.comHalozyme Therapeutics (HALO) Projected to Post Earnings on TuesdayMay 5 at 2:47 AM | americanbankingnews.comQ1 EPS Forecast for Halozyme Therapeutics Boosted by AnalystHalozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Zacks Research increased their Q1 2025 earnings per share estimates for shares of Halozyme Therapeutics in a note issued to investors on Tuesday, April 29th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical cMay 3 at 6:49 AM | marketbeat.comZacks Research Issues Negative Estimate for HALO EarningsHalozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Research analysts at Zacks Research decreased their Q1 2027 earnings per share (EPS) estimates for Halozyme Therapeutics in a note issued to investors on Tuesday, April 29th. Zacks Research analyst R. Department now expects that the biophaMay 2 at 8:56 AM | marketbeat.comAquatic Capital Management LLC Buys Shares of 35,501 Halozyme Therapeutics, Inc. (NASDAQ:HALO)Aquatic Capital Management LLC bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 35,501 sharMay 2 at 5:19 AM | marketbeat.comQ1 EPS Forecast for Halozyme Therapeutics Lowered by AnalystMay 2 at 3:37 AM | americanbankingnews.comRenaissance Technologies LLC Cuts Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Renaissance Technologies LLC lessened its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 89.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 26,110 shares of the biopharmaceuticalMay 2 at 3:33 AM | marketbeat.comHalozyme Therapeutics: Still Undervalued Ahead Of EarningsMay 1, 2025 | seekingalpha.comHalozyme Therapeutics: Still Undervalued Ahead Of EarningsMay 1, 2025 | seekingalpha.comPDT Partners LLC Raises Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)PDT Partners LLC raised its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 382.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 84,062 shares of the biopharmaceutical company'May 1, 2025 | marketbeat.comHalozyme Therapeutics (HALO) to Release Quarterly Earnings on TuesdayHalozyme Therapeutics (NASDAQ:HALO) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-halozyme-therapeutics-inc-stock/)May 1, 2025 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD lowered its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 4.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,218,326 shares of the biopMay 1, 2025 | marketbeat.comDimensional Fund Advisors LP Purchases 47,795 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Dimensional Fund Advisors LP grew its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 2.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,933,560 shares of the biopharmaMay 1, 2025 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Director Sells $271,483.89 in StockHalozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) Director Jeffrey William Henderson sold 4,497 shares of the firm's stock in a transaction on Monday, April 28th. The stock was sold at an average price of $60.37, for a total transaction of $271,483.89. Following the transaction, the director now directly owns 28,611 shares of the company's stock, valued at approximately $1,727,246.07. This trade represents a 13.58 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.April 30, 2025 | marketbeat.comMGO One Seven LLC Raises Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)MGO One Seven LLC lifted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 123.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 12,037 shares of the biopharmaceutical company's stock after buying an additionApril 30, 2025 | marketbeat.comPinebridge Investments L.P. Grows Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Pinebridge Investments L.P. grew its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 42.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 39,167 shares of the biopharmaceutical companApril 30, 2025 | marketbeat.comHalozyme’s CIDP drug nears EU approval after CHMP nodApril 29, 2025 | investing.comHalozyme to Report First Quarter 2025 Financial and Operating ResultsApril 28, 2025 | prnewswire.comHalozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)April 28, 2025 | prnewswire.comTower Research Capital LLC TRC Buys 16,002 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Tower Research Capital LLC TRC raised its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 388.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 20,126 shares of the biopharmaceutical company's stock after purchasApril 28, 2025 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Halozyme Therapeutics (NASDAQ:HALO)April 28, 2025 | americanbankingnews.comHC Wainwright Reiterates Buy Rating for Halozyme Therapeutics (NASDAQ:HALO)HC Wainwright reissued a "buy" rating and set a $72.00 price target on shares of Halozyme Therapeutics in a research note on Friday.April 27, 2025 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Acquired by Snyder Capital Management L PSnyder Capital Management L P lifted its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 2.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,168,453 shares of the biopharmaceutical company'sApril 27, 2025 | marketbeat.comFirst Trust Advisors LP Sells 17,291 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)First Trust Advisors LP decreased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 2.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 859,572 shares of the biopharmaceutical company's stock after seApril 27, 2025 | marketbeat.comHancock Whitney Corp Purchases 104,015 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Hancock Whitney Corp boosted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 619.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 120,811 shares of the biopharmaceutical company's stock after acqApril 26, 2025 | marketbeat.comFuller & Thaler Asset Management Inc. Has $42.45 Million Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Fuller & Thaler Asset Management Inc. boosted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 7.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 887,852 shares of the biopharmaceutical company'sApril 26, 2025 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by CANADA LIFE ASSURANCE CoCANADA LIFE ASSURANCE Co cut its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 26.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 107,140 shares of the biopharmaceutical company's stoApril 26, 2025 | marketbeat.com1HALO : Deep Dive Into Halozyme Therapeutics Stock: Analyst Perspectives (5 Ratings)April 25, 2025 | benzinga.comMetLife Investment Management LLC Buys 10,538 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)MetLife Investment Management LLC boosted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 7.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 145,265 shares of the biopharmaceutical company's stock after buying an additApril 25, 2025 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Recommendation of "Moderate Buy" by AnalystsHalozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) has received a consensus rating of "Moderate Buy" from the ten analysts that are presently covering the firm, MarketBeat reports. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company. The avApril 25, 2025 | marketbeat.comHalozyme Sues Merck Over Subcutaneous Keytruda Formulation, Seeks Injunctive ReliefApril 24, 2025 | msn.comHalozyme files patent lawsuit against Merck over injectable KeytrudaApril 24, 2025 | msn.comHalozyme Therapeutics (HALO) Files Lawsuit Against Merck Over Patent InfringementApril 24, 2025 | gurufocus.comHalozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda FormulationApril 24, 2025 | prnewswire.comFayez Sarofim & Co Invests $359,000 in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Fayez Sarofim & Co purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 7,500 shares of the biopharmaceutical company's stock,April 24, 2025 | marketbeat.comCapital World Investors Purchases Shares of 748,230 Halozyme Therapeutics, Inc. (NASDAQ:HALO)Capital World Investors acquired a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 748,230 shares of the biopharmaceuticaApril 24, 2025 | marketbeat.comCanada Pension Plan Investment Board Has $8.52 Million Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Canada Pension Plan Investment Board lifted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 77.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 178,200 shares of the biopharmaceutical company's stocApril 24, 2025 | marketbeat.comMijuško ŠibalićApril 23, 2025 | entrepreneur.comHalozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $58.00 at JPMorgan Chase & Co.JPMorgan Chase & Co. boosted their price target on Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a research note on Monday.April 23, 2025 | marketbeat.comHere's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 YearsApril 22, 2025 | benzinga.comMesirow Institutional Investment Management Inc. Buys 82,643 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Mesirow Institutional Investment Management Inc. grew its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 37.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 302,148 shares of the biopharmaceutical company's stocApril 22, 2025 | marketbeat.comBI Asset Management Fondsmaeglerselskab A S Buys 132,795 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)BI Asset Management Fondsmaeglerselskab A S boosted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 45.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 427,207 sApril 22, 2025 | marketbeat.comEpoch Investment Partners Inc. Has $37.21 Million Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Epoch Investment Partners Inc. reduced its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 8.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 778,311 shares of the biopharmaceuticalApril 22, 2025 | marketbeat.comGuggenheim Capital LLC Sells 12,916 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Guggenheim Capital LLC lowered its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 16.4% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 65,949 shares of the biopharmaceutical company's stock after selling 12,916 shares duApril 22, 2025 | marketbeat.comA Hidden Gem in the Biotech Sector: Halozyme Therapeutics (HALO) April 22, 2025 | wallstreetzen.comRaymond James Financial Inc. Takes Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Raymond James Financial Inc. acquired a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 456,774 shares of the biopharmaceutical company's stock, valued at aApril 21, 2025 | marketbeat.comJ.P. Morgan Remains a Hold on Halozyme (HALO)April 20, 2025 | markets.businessinsider.comXTX Topco Ltd Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)XTX Topco Ltd bought a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 14,459 shares of the biopharmaceutical company's stock, valued at approximApril 20, 2025 | marketbeat.comEnvestnet Asset Management Inc. Sells 42,665 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Envestnet Asset Management Inc. lessened its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 12.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 302,613 shares of the biopharmaceutical coApril 19, 2025 | marketbeat.com Get Halozyme Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Email Address HALO Media Mentions By Week HALO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HALO News Sentiment▼0.810.73▲Average Medical News Sentiment HALO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HALO Articles This Week▼2511▲HALO Articles Average Week Get Halozyme Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BIIB News Today UTHR News Today BMRN News Today INCY News Today EXEL News Today NBIX News Today EXAS News Today RGEN News Today MDGL News Today IONS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HALO) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Halozyme Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy HALO Stock Free HALO Stock Alerts